{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:23:58Z","timestamp":1767835438335,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2022\/004698"],"award-info":[{"award-number":["CRG\/2022\/004698"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Biochemistry and Biophysics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.abb.2024.110019","type":"journal-article","created":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T14:04:23Z","timestamp":1714313063000},"page":"110019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A structure-based pharmacophore modelling approach to identify and design new neprilysin (NEP) inhibitors: An in silico-based investigation"],"prefix":"10.1016","volume":"756","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3632-9452","authenticated-orcid":false,"given":"Shikha","family":"Thakur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurba","family":"Sinhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8719-5258","authenticated-orcid":false,"given":"Hemant R.","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.abb.2024.110019_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1096\/fasebj.11.5.9141502","article-title":"Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX","volume":"11","author":"Turner","year":"1997","journal-title":"Faseb. J."},{"issue":"1","key":"10.1016\/j.abb.2024.110019_bib2","first-page":"87","article-title":"Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology","volume":"45","author":"Roques","year":"1993","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.abb.2024.110019_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13036-017-0093-0","article-title":"Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure","volume":"12","author":"Fu","year":"2018","journal-title":"J. Biol. Eng."},{"issue":"20","key":"10.1016\/j.abb.2024.110019_bib4","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.2174\/1568026619666190826163536","article-title":"Therapeutic progress and knowledge basis on the natriuretic peptide system in heart failure","volume":"19","author":"Fu","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"8","key":"10.1016\/j.abb.2024.110019_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104001","article-title":"Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease","volume":"9","author":"Webster","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.abb.2024.110019_bib6","series-title":"Neprilysin Inhibitors and Risk of Alzheimer's Disease: A Future Perspective","author":"Ali","year":"2023"},{"issue":"6","key":"10.1016\/j.abb.2024.110019_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A test in context: neprilysin: function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.abb.2024.110019_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ndt\/gfu269","article-title":"Neprilysin inhibition in chronic kidney disease","volume":"30","author":"Judge","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.abb.2024.110019_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11897-015-0270-8","article-title":"The role of neprilysin inhibitors in cardiovascular disease","volume":"12","author":"Mills","year":"2015","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.abb.2024.110019_bib10","series-title":"Neprilysin Inhibitors in Heart Failure: the Science, Mechanism of Action, Clinical Studies, and Unanswered Questions","author":"Bozkurt","year":"2022"},{"issue":"7","key":"10.1016\/j.abb.2024.110019_bib11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41440-022-00923-2","article-title":"Angiotensin receptor-neprilysin inhibitors for hypertension-hemodynamic effects and relevance to hypertensive heart disease","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens. Res."},{"issue":"9","key":"10.1016\/j.abb.2024.110019_bib12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FPC.0b013e328363c137","article-title":"Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"23","author":"Pare","year":"2013","journal-title":"Pharmacogenetics Genom."},{"issue":"3","key":"10.1016\/j.abb.2024.110019_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40292-015-0112-5","article-title":"Angiotensin II receptor blocker neprilysin inhibitor (ARNI): new avenues in cardiovascular therapy","volume":"22","author":"Volpe","year":"2015","journal-title":"High Blood Pres. Cardiovasc. Prev."},{"issue":"1","key":"10.1016\/j.abb.2024.110019_bib14","first-page":"88","volume":"8","author":"Bozkurt","year":"2023","journal-title":"Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions"},{"issue":"3","key":"10.1016\/j.abb.2024.110019_bib15","doi-asserted-by":"crossref","first-page":"E307","DOI":"10.1152\/ajpendo.00234.2021","article-title":"Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with beta-cell dysfunction","volume":"322","author":"Esser","year":"2022","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.abb.2024.110019_bib16","series-title":"Effects of Neprilysin and Neprilysin Inhibitors on Glucose Homeostasis: Controversial Points and a Promising Arena","author":"AlAnazi","year":"2023"},{"key":"10.1016\/j.abb.2024.110019_bib17","volume":"14","author":"Hu","year":"2023"},{"issue":"5","key":"10.1016\/j.abb.2024.110019_bib18","first-page":"513","article-title":"Neprilysin 4: an essential peptidase with multifaceted physiological relevance","volume":"404","author":"Buhr","year":"2023"},{"key":"10.1016\/j.abb.2024.110019_bib19","first-page":"105","article-title":"Neutral endopeptidase (NEP) inhibitors\u2013thiorphan, sialorphin, and its derivatives exert anti-proliferative activity towards colorectal cancer cells in vitro","volume":"307","author":"Mizerska-Kowalska","year":"2019"},{"issue":"1","key":"10.1016\/j.abb.2024.110019_bib20","first-page":"9952","article-title":"Repurposing of neprilysin inhibitor \u2018sacubitrilat\u2019as an anti-cancer drug by modulating epigenetic and apoptotic regulators","volume":"13","author":"Kumbhar","year":"2023"},{"issue":"2","key":"10.1016\/j.abb.2024.110019_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharep.2018.12.002","article-title":"Angiotensin converting enzyme and neprilysin inhibition alter pain response in dexhamethasone-induced hypertensive rats","volume":"71","author":"Aykan","year":"2019","journal-title":"Pharmacol. Rep."},{"issue":"2","key":"10.1016\/j.abb.2024.110019_bib22","first-page":"149","article-title":"Substance P and thiorphan synergically enhance angiogenesis in wound healing","volume":"13","author":"Um","year":"2016"},{"issue":"7","key":"10.1016\/j.abb.2024.110019_bib23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1089\/omi.2021.0080","article-title":"Broadening COVID-19 interventions to drug innovation: neprilysin pathway as a friend, foe, or promising molecular target?","volume":"25","author":"Rex","year":"2021","journal-title":"OMICS"},{"issue":"3","key":"10.1016\/j.abb.2024.110019_bib24","first-page":"171","article-title":"Long-term neprilysin inhibition\u2014implications for ARNIs","volume":"14","author":"Campbell","year":"2017"},{"issue":"9","key":"10.1016\/j.abb.2024.110019_bib25","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2174\/1568026611313090006","article-title":"Methods and applications of structure based pharmacophores in drug discovery","volume":"13","author":"Pirhadi","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"10.1016\/j.abb.2024.110019_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/minf.201200169","article-title":"Multiple e\u2010pharmacophore modeling combined with high\u2010throughput virtual screening and docking to identify potential inhibitors of \u03b2\u2010secretase (BACE1)","volume":"32","author":"Palakurti","year":"2013","journal-title":"Molecular informatics"},{"issue":"1","key":"10.1016\/j.abb.2024.110019_bib27","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1038\/s41598-021-83626-x","article-title":"Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein","volume":"11","author":"Opo","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.abb.2024.110019_bib28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/ph16030330","article-title":"Inhibiting Leishmania donovani sterol methyltransferase to identify lead compounds using molecular modelling","volume":"16","author":"Sakyi","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"16","key":"10.1016\/j.abb.2024.110019_bib29","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem Rev"},{"key":"10.1016\/j.abb.2024.110019_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2021.108114","article-title":"Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors","volume":"112","author":"Shaikh","year":"2022","journal-title":"J. Mol. Graph. Model."},{"issue":"4","key":"10.1016\/j.abb.2024.110019_bib31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1017\/S0033583515000190","article-title":"In silico ADME\/T modelling for rational drug design","volume":"48","author":"Wang","year":"2015","journal-title":"Q. Rev. Biophys."},{"issue":"2","key":"10.1016\/j.abb.2024.110019_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/jmbi.1999.3492","article-title":"Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon","volume":"296","author":"Oefner","year":"2000","journal-title":"J. Mol. Biol."}],"container-title":["Archives of Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986124001383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986124001383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T21:11:26Z","timestamp":1715461886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003986124001383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":32,"alternative-id":["S0003986124001383"],"URL":"https:\/\/doi.org\/10.1016\/j.abb.2024.110019","relation":{},"ISSN":["0003-9861"],"issn-type":[{"value":"0003-9861","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A structure-based pharmacophore modelling approach to identify and design new neprilysin (NEP) inhibitors: An in silico-based investigation","name":"articletitle","label":"Article Title"},{"value":"Archives of Biochemistry and Biophysics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abb.2024.110019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110019"}}